MCRN 004 – The LAURENTIANS Trial
COMING FALL 2017!
Daratumumab (Darzalex®) is the first monoclonal antibody for the treatment of myeloma to be approved by Health Canada. Presently, it is not reimbursed by any public drug plan, denying access to those to patients in need for the time being. LAURENTIANS will not only provide access to daratumumab for eligible patients across the country, but it will also answer the question of how to optimize the use of expensive drugs using a rational and cost-effective approach.
Led by Dr Michael Sebag at the McGill University Health Centre in Montreal, this open-label trial is planned to recruit a total of 120 patients across Canada into two study arms. One group will receive daratumumab, cyclophosphamide, dexamethasone and pomalidomide (Pomalyst®). The other group will receive the same treatment regimen, however pomalidomide will only be added when the participant’s disease progresses. Stay tuned for more details.